Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy

Paediatrics and International Child Health

Volumn 36, Issue 1, 2016, Pages 22-27

  Sharma, Rajni ^a   Seth, Anju ^a   Chandra, Jagdish ^a   Gohain, Suraj ^a   Kapoor, Seema ^b   Singh, Pratiksha ^b   Pemde, Harish ^a  

^a KALAWATI SARAN CHILDREN'S HOSPITAL   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Deferiprone; Growth hormone deficiency; Short stature

Indexed keywords

DEFERIPRONE; FERRITIN; GROWTH HORMONE; HEMOGLOBIN; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CHILD; DELAYED PUBERTY; DIABETES MELLITUS; ENDOCRINE DISEASE; FEMALE; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; SHORT STATURE; SUBCLINICAL HYPOTHYROIDISM; THALASSEMIA MAJOR; YOUNG ADULT; ADOLESCENT DEVELOPMENT; BETA-THALASSEMIA; COMPLICATION; ENDOCRINE SYSTEM DISEASES; PROSPECTIVE STUDY;

ADOLESCENT; ADOLESCENT DEVELOPMENT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; PROSPECTIVE STUDIES; PYRIDONES;

EID: 85009727880     PISSN: 20469047     EISSN: 20469055     Source Type: Journal    
DOI: 10.1179/2046905514Y.0000000160     Document Type: Article

References (28)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-31.
2. Piga A, Roggero S, Salussolia I, Massano D, Serra M, Longo F. Deferiprone. Ann N Y Acad Sci. 2010;1202:75-8.
3. Berdoukas V, Farmaki K, Carson S, Wood J, Coates T. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med. 2012;3:119-29.
4. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516-20.
5. Aydinok Y, Darcan S, Polat A, Kavakli K, Nigli G, Coker M, et al. Endocrine complications in patients with beta-thalassemia major. J Trop Pediatr. 2002;48:50-4.
6. Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. Hemoglobin. 2006;30:257-62.
7. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassemia major. Br J Haematol. 2010;148:466-75.
8. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Molec Dis. 2011;47:33-40.
9. Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;6 (suppl 1):158-69.
10. Platis O, Anagnostopoulos G, Farmaki K, Posantzis M, Gotsis E, Tolis G. Glucose metabolism disorders improvement in patients with thalassemia major after 24-36 months of intensive chelation therapy. Pediatr Endocrinol Rev. 2004;2 (suppl 2):279-81.
11. Agarwal DK, Agarwal KN, Upadhyay SK, Mittal R, Prakash R, Rai S. Indian Pediatr. 1992;29:1203-82.
12. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976;51:170-9.
13. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and the Wrist, 2nd edn. Stanford, CA: Stanford University Press, 1959.
14. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Report of a WHO/IDF consultation. Geneva: WHO, 2006.
15. Italian Working Group on Endocrine Complications in Nonendocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol (Oxf). 1995;42:581-6.
16. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in beta- thalassemia major in a developing country. J Pediatr Endocrinol Metab. 2000;13:651-6.
17. Najafipour F, Aliasgarzadeh A, Aghamohamadzadeh N, Bahrami A, Mobasri M, Niafar M, et al. A cross-sectional study of metabolic and endocrine complications in betathalassemia major. Ann Saudi Med. 2008;28:361-6.
18. Raiola G, Galati MC, De Sanctis V, Caruso Nicoletti M, Pintor C, De Simone M, et al. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab. 2003;16 (suppl 2):259-66.
19. Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanctis V, Melevendi C, et al. Growth and sexual maturation in thalassemia major. J Pediatr. 1985;106:150-5.
20. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with thalassaemia major. Pediatr Endocrinol Rev. 2007;5:642-8.
21. Chern JP, Lin KH. Hypoparathyroidism in transfusiondependent patients with beta-thalassemia. J Pediatr Hematol Oncol. 2002;24:291-3.
22. Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT. Serum ferritin levels and endocrinopathy in medically treated patients with b thalassemia major. Ann Hematol. 2012;91:1107-14.
23. Chatterjee R, Bajoria R. Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Ann NY Acad Sci. 2010;1202:100-14.
24. Mohammadian S, Bazrafshan HR, Sadeghi-Nejad A. Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab. 2003;16:957-64.
25. Theodoridis C, Ladis V, Papatheodorou A, Berdousi H, Palamidou F, Evagelopoulou C, et al. Growth and management of short stature in thalassemia major. J Pediatr Endocrinol Metab. 1998;11 (suppl 3):835-44.
26. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M, et al. Short stature and failure of pubertal development in thalassemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr. 1997;156:777-83.
27. Chrysis DC, Alexandrides TK, Koromantzou E, Georgopoulos N, Vassilakos P, Kiess W, et al. Novel application of IGF-I and IGFBP-3 generation tests in the diagnosis of growth hormone axis disturbances in children with beta-thalassemia. Clin Endocrinol (Oxf). 2001;54:253-9.
28. Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann NY Acad Sci. 2010;1202:123-8.